Background: Previous studies on the association between diet and breast cancer are mostly from Western populations, and data from Middle East countries are scarce, where the prevalence of breast cancer is high; therefore, it ranks first among other cancers. This population-based case-control study aimed to investigate the relationship between a Mediterranean-style diet and breast cancer among Iranian women.
Methods: In the current study, 350 new cases of breast cancer and 700 age- and socioeconomic status-matched controls were enrolled. We evaluated the dietary intakes of participants by using a 106-item Willett-format semi-quantitative dish-based food frequency questionnaire (SQ-FFQ). We calculated the Mediterranean diet score according to the dietary intakes of participants. In addition, using pre-tested questionnaires, we collected information on potential confounding variables.
Results: In this study, we found a significant inverse association between the Mediterranean diet and breast cancer so that after controlling for potential confounders, individuals in the highest tertile of the Mediterranean diet score compared with those in the lowest tertile were 57% less likely to have breast cancer [odds ratio (OR): 0.43, 95% confidence interval (CI): 0.28-0.67]. Such an inverse association was also observed for postmenopausal women. Similarly, after controlling for potential confounding variables, high adherence to the Mediterranean dietary pattern was associated with lower odds of breast cancer (OR: 0.37, 95% CI: 0.23-0.60). However, this relationship was not significant among premenopausal women.
Conclusion: We found that adherence to Mediterranean dietary pattern was associated with reduced odds of breast cancer. Studies with prospective design are needed to further examine this association.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393472 | PMC |
http://dx.doi.org/10.3389/fnut.2023.1140014 | DOI Listing |
Int J Environ Health Res
January 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Previous research yields inconsistent findings on the association between air pollution and breast cancer risk, with no definitive causal relationship established. To address this, we conducted a two-sample Mendelian randomization study on data from the IEU open GWAS databases and the Breast Cancer Association Consortium to explore the potential link between air pollution (including PM, PM absorbance, PM, PM, NO, and NO) and breast cancer risk. We found that PM (odds ratio (OR) = 1.
View Article and Find Full Text PDFJ Cancer Res Ther
December 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.
Background: The low incidence and poor prognosis primary trastuzumab resistance (PTR) in HER2-positive breast cancer has limited research into possible treatments. Thus, it remains unclear whether this group of patients could benefit from nontargeting HER2 antiangiogenic therapy.
Patients And Methods: We collected the medical data for HER2-positive patients with PTR who received apatinib 250 mg and trastuzumab-based chemotherapy (ATBC) between March 18, 2017, and March 31, 2022.
J Cancer Res Ther
December 2024
School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, China.
Tumor-infiltrating lymphocytes (TILs) are key components of the tumor microenvironment (TME) and serve as prognostic markers for breast cancer. Patients with high TIL infiltration generally experience better clinical outcomes and extended survival compared to those with low TIL infiltration. However, as the TME is highly complex and TIL subtypes perform distinct biological functions, TILs may only provide an approximate indication of tumor immune status, potentially leading to biased prognostic results.
View Article and Find Full Text PDFCancer Nurs
January 2025
Author Affiliations: Department Research, Hospital Germans Trias i Pujol, Universitat Autonòma de Barcelona; and NURECARE Research Group, Institut d'Investigació i Hospital Germans Trias i Pujol (IGTP), Ctra de Can Ruti, Camí de les Escoles (Dr Huertas-Zurriaga); Department Research, Institut Català Oncologia-Hospital Germans Trias i Pujol; Universitat Autonòma de Barcelona; GRIN Group, IDIBELL, Institute of Biomedical Research; and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Cabrera-Jaime); Tecnocampus University and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Navarri); Oncology Department, Hereditarian Cancer Program, Institut Català Oncologia-Hospital Germans Trias i Pujol, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona (Dr Teruel-Garcia); and Nursing Research Group in Vulnerability and Health (GRIVIS); and Nursing Department, Faculty of Medicine, Universitat Autònoma de Barcelona (Dr Leyva-Moral), Badalona, Spain.
Background: Breast cancer survivors face unique challenges in breastfeeding decisions. Limited research exists on the experiences and decision-making processes of young women with breast cancer regarding breastfeeding.
Objective: To explain the decision-making processes of young women with breast cancer in relation to breastfeeding throughout the cancer trajectory.
Breast Cancer Res Treat
January 2025
Department of Oncology, University of Torino, Via Nizza 44, 10126, Turin, Italy.
Purpose: Mammary carcinoma is comprised heterogeneous groups of cells with different metastatic potential. 4T1 mammary carcinoma cells metastasized to heart (4THM), liver (4TLM) and brain (4TBM) and demonstrate cancer-stem cell phenotype. Using these cancer cells we found thatTGF-β is the top upstream regulator of metastatic process.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!